Lucid Diagnostics Inc. Common StockLUCD
Scheduled
Lucid Diagnostics Inc. Common Stock Canaccord Genuity's 46th Annual Growth Conference
Review the key takeaways and the transcript of this earnings call.
PeriodFY 0
Key takeaways
- Lucid Diagnostics operates in the esophageal cancer prevention space, focusing on detecting Barrett's esophagus, a precancerous condition with an approximately 80% fatality rate if untreated.
- The company's Esoguard test is a non-invasive molecular diagnostic test performed in about 45 seconds in an office setting, with a high negative predictive value for ruling out precancerous conditions and cancer.
- Standard care currently relies on upper endoscopy, which has poor compliance rates below 10%, and Esoguard serves as a triage alternative to improve early detection and prevention.
- Lucid has performed about 60,000 tests to date, maintaining quarterly test volumes around 2,500 to 3,000, initially focusing on health testing events and now shifting toward traditional physician engagement and VA centers.
- Concert, a laboratory benefit manager covering about 9 million lives, issued a positive coverage policy for Esoguard, with three plans publicly adopting it.
- Major commercial payers United and Cigna have published endoscopy guidelines recognizing a positive Esoguard test as an appropriate indication for upper endoscopy.
- Lucid is on the VA federal supply schedule at the Medicare rate of approximately $1,900 and is actively contracting with individual VA centers, expecting revenue from these contracts in coming quarters.
- Medicare established a payment rate for Esoguard in 2021 but coverage has been delayed due to bureaucratic obstacles despite a positive 2023 expert panel review (CCaC meeting).
- Lucid submitted a request for reconsideration in November 2023 and expects a draft Local Coverage Determination (LCD) to flip from non-coverage to coverage, which would enable scaling commercial efforts and reimbursement claims with a one-year lookback.
- The company has raised capital to extend its runway and plans to raise growth capital once Medicare coverage is secured to expand its commercial team and market penetration.
- Esoguard targets a large addressable population of approximately 30 million patients in the US based on established guidelines, with a test price just under $2,000.
- Patient compliance with the Esoguard test is about 95%, with high patient satisfaction and over 85% compliance for follow-up endoscopy after a positive test.
- Lucid is developing a healthcare economics and outcomes research model to demonstrate cost-effectiveness to commercial payers.
- The company is focused on expanding commercial payer coverage, VA engagement, and health system integration, especially electronic health record (EHR) integration, to accelerate volume and revenue post-Medicare coverage.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring